Sweden's Devyser Q2 prelim sales weaken on distributor inventory build-up
Sweden's Devyser Q2 prelim sales weaken on distributor inventory build-up
Overview
Sweden diagnostics kit maker's preliminary Q2 sales weakened due to distributor inventory build-up
Company expects softer sales growth to main distributor for rest of 2026
Liquidity and cash flow forecast remain satisfactory despite weaker sales
Outlook
Devyser expects sales to its largest distributor to grow at a softer rate for rest of 2026
Company anticipates sales to largest distributor to normalize from 2027 onwards
Result Drivers
DISTRIBUTOR INVENTORY BUILD-UP - Co said Q2 sales were negatively impacted by inventory build-up at its largest distributor, reducing purchasing needs during the period
DIRECT AND OTHER MARKETS - Co said direct markets and other distributor markets continued to deliver positive sales growth
Company press release: ID:nMFN1J7Y9t
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Sales |
| SEK 60.20 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Devyser Diagnostics AB is SEK164.00, about 97.8% above its July 2 closing price of SEK82.90
The stock recently traded at 24 times the next 12-month earnings vs. a P/E of 25 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)